PH12014500736A1 - Formulation for prevention or treatment of diabetes - Google Patents
Formulation for prevention or treatment of diabetesInfo
- Publication number
- PH12014500736A1 PH12014500736A1 PH1/2014/500736A PH12014500736A PH12014500736A1 PH 12014500736 A1 PH12014500736 A1 PH 12014500736A1 PH 12014500736 A PH12014500736 A PH 12014500736A PH 12014500736 A1 PH12014500736 A1 PH 12014500736A1
- Authority
- PH
- Philippines
- Prior art keywords
- diabetes
- complications
- metformin
- patient
- pharmaceutically acceptable
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 2
- 229960003105 metformin Drugs 0.000 abstract 2
- 230000000291 postprandial effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 229940029980 drug used in diabetes Drugs 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 229960001729 voglibose Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a formultaion of voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof which is provided for the reduction, in a substantially equivalent or increased amount compared to single administration of metformin, of HbAlc levels, fasting and postprandial blood gllucose levels and postprandial blood glucose variation, or glycemic variability and also the reduction of the frequency of hypoglycemia, cardiovascular complications, and gastrointestinal complications in a patient with no prior experience of anti-diabetes medication or a patient in the early stage of type 2 diabetes showing a HbAlc (%) level of 7 to 11%, and ultimately, is able to effectively treat diabetes in patients in the early stage of type 2 diabetes and to minimize adverse effects, side-effects, and risk of complications.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130024157A KR101336499B1 (en) | 2013-03-06 | 2013-03-06 | Combination composition for prevention or treatment of diabetes |
| PCT/KR2014/001455 WO2014137090A1 (en) | 2013-03-06 | 2014-02-24 | Formulation for prevention or treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014500736A1 true PH12014500736A1 (en) | 2014-06-30 |
Family
ID=49987171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2014/500736A PH12014500736A1 (en) | 2013-03-06 | 2014-02-24 | Formulation for prevention or treatment of diabetes |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2964211A4 (en) |
| JP (1) | JP2016509065A (en) |
| KR (1) | KR101336499B1 (en) |
| CN (1) | CN104027328A (en) |
| BR (1) | BR112015018934A2 (en) |
| HK (1) | HK1212587A1 (en) |
| PH (1) | PH12014500736A1 (en) |
| TW (1) | TW201434463A (en) |
| WO (1) | WO2014137090A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118448058B (en) * | 2024-06-26 | 2024-09-27 | 四川大学华西医院 | Prediction system and construction method of diabetes and hypertension based on gastrointestinal electrical signals |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| US20080207490A1 (en) * | 2005-07-07 | 2008-08-28 | Postech Foundation | Glucose Uptake Modulator and Method for Treating Diabetes or Diabetic Complications |
| CN101590007A (en) * | 2008-05-27 | 2009-12-02 | 北京瑞伊人科技发展有限公司 | A kind of metformin hydrochloride/voigelibo sugar-lowering oral preparation compositions and preparation thereof |
| KR101189639B1 (en) * | 2008-12-15 | 2012-10-12 | 씨제이제일제당 (주) | Oral formulations comprising metformin and &-glycosidase inhibitor and processes for the preparation thereof |
| CN102133402B (en) * | 2011-03-24 | 2013-06-12 | 首都医科大学附属北京同仁医院 | Application of cystic fibrosis transmembrane transduction regulating factor inhibitor to preparation of medicaments for treating diabetes |
-
2013
- 2013-03-06 KR KR1020130024157A patent/KR101336499B1/en not_active Expired - Fee Related
-
2014
- 2014-02-24 PH PH1/2014/500736A patent/PH12014500736A1/en unknown
- 2014-02-24 HK HK16100385.5A patent/HK1212587A1/en unknown
- 2014-02-24 WO PCT/KR2014/001455 patent/WO2014137090A1/en not_active Ceased
- 2014-02-24 JP JP2015559188A patent/JP2016509065A/en active Pending
- 2014-02-24 BR BR112015018934A patent/BR112015018934A2/en not_active IP Right Cessation
- 2014-02-24 EP EP14760276.7A patent/EP2964211A4/en not_active Withdrawn
- 2014-02-26 TW TW103106464A patent/TW201434463A/en unknown
- 2014-03-05 CN CN201410078942.1A patent/CN104027328A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2964211A4 (en) | 2016-08-31 |
| EP2964211A1 (en) | 2016-01-13 |
| HK1212587A1 (en) | 2016-06-17 |
| JP2016509065A (en) | 2016-03-24 |
| TW201434463A (en) | 2014-09-16 |
| KR101336499B1 (en) | 2013-12-03 |
| WO2014137090A1 (en) | 2014-09-12 |
| BR112015018934A2 (en) | 2017-07-18 |
| CN104027328A (en) | 2014-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rochette et al. | Diabetes, oxidative stress and therapeutic strategies | |
| WO2012125830A3 (en) | Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control | |
| EA201300522A1 (en) | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| WO2012055967A3 (en) | Treating diabetes melitus using insulin injections administered with varying injection intervals | |
| MX2013011174A (en) | Prevention of hypoglycaemia in diabetes mellitus type 2 patients. | |
| HK1210699A1 (en) | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy | |
| PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| EA201792030A1 (en) | TREATMENT OF PATIENTS WITH DIABETES MELLITUS TYPE 2 | |
| FI3352735T3 (en) | Sustained release olanzapine formulations | |
| PH12014500736A1 (en) | Formulation for prevention or treatment of diabetes | |
| WO2011128782A3 (en) | Compositions and methods for treating type ii diabetes and related disorders | |
| JP2016510040A5 (en) | ||
| PH12019501028A1 (en) | Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia | |
| NZ708511A (en) | Methods for controlling blood pressure and reducing dyspnea in heart failure | |
| WO2011075611A8 (en) | Compositions and methods for non-invasive treatment of chronic complications of diabetes | |
| Lopatin et al. | The acute and chronic effects of ivabradine on the parameters of central aortic pressure in patients with stable coronary artery disease | |
| TH155604A (en) | Medicines for the prevention or treatment of diabetes | |
| Yamane | Cardiac arrest in a child due to inadvertent intravascular administration: case report | |
| Harden et al. | D105 ICU QUALITY AND SAFETY: IMPROVEMENT OPPORTUNITIES: Shock Secondary To Amlodipine Overdose Successfully Treated With High Dose Insulin Therapy | |
| Avram et al. | EFFECT OF NICORANDIL IN PATIENTS WITH REFRACTORY ANGINA AND ADVANCED CORONARY ARTERY DISEASE | |
| Scarano | Incomplete atrioventricular block in an elderly patient: case report | |
| Vilaboa Pedrosa | Hypotension: case report | |
| Morales | Bradycardia and hypotension: case report | |
| Kale | Various toxicities: 10 case reports |